Zosuquidar trihydrochloride

• CAT Number: I010049
• CAS Number: 167465-36-3
• Molecular Formula: C₃₂H₃₁FN₃O.3HCl
• Molecular Weight: 636.99
• Purity: ≥95%
• Synonyms: Zosuquidar Trihydrochloride; 167465-36-3; Ly335979; Zosuquidar HCl; LY 335979
• Target: P-glycoprotein
• Solubility: Soluble in DMSO, not in water
• Storage: 0 - 4 °C for short term, or -20 °C for long term
• IUPAC Name: (2R)-1-[4-[(2S,4R)-3,3-difluoro-11-tetracyclo[10.4.0.02,4.05,10]hexadeca-1(16),5,7,9,12,14-hexaenyl]piperazin-1-yl]-3-quinolin-5-yloxypropan-2-ol;trihydrochloride
• InChI: InChI=1S/C32H31F2N3O2.3ClH/c33-32(34)29-22-7-1-3-9-24(22)31(25-10-4-2-8-23(25)30(29)32)37-17-15-36(16-18-37)19-21(38)20-39-28-13-5-12-27-26(28)11-6-14-35-27;;;/h1-14,21,29-31,38H,15-20H2;3*1H/t21-,29-,30+,31?;;;/m1.../s1
• InChIKey: ZPFVQKPWGDRLHL-ZLYBXYBFSA-N
• SMILES: C1CN(CCN1CC(COC2=CC=CC3=C2C=CC=N3)O)C4C5=CC=CC=C5C6C(C6(F)F)C7=CC=CC=C47.Cl.Cl.Cl

Zosuquidar trihydrochloride (CAT: I010049) is a selective inhibitor of P-glycoprotein (P-gp), a protein involved in multidrug resistance. It acts by blocking the efflux of anticancer drugs from cancer cells, thereby enhancing the effectiveness of chemotherapy. Zosuquidar has been studied for its potential to overcome drug resistance in various cancers, including leukemia, breast cancer, and lung cancer. It has shown promising results in preclinical and clinical studies, both as a single agent and in combination with other chemotherapeutic drugs. Zosuquidar trihydrochloride represents a potential strategy to improve the efficacy of cancer treatments by overcoming multidrug resistance.